HR-positive/HER2-negative is the most common subtype of breast cancer in women. HR-positive/HER2-negative metastatic breast ...

This year's American Society of Clinical Oncology (ASCO) meeting delivered a packed agenda of breast cancer research, with ...

A new medication found to reduce the chance of the most common types of breast cancer recurring will be available to many ...

For the first time in Australia, a drug that can delay the growth of tumours is available under the Pharmaceutical Benefits ...

Diagnosis and treatment of breast cancer can differ for patients in rural communities compared with those in urban ...

DelveInsight's HER2-low Cancers Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging HER2-low ...

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the ...

Datroway (datopotamab deruxtecan) is the first TROP2-directed therapy approved for advanced lung cancer in the U.S.

A potentially life-saving treatment for early-stage breast cancer will become much more affordable for hundreds of ...

Ananda Lewis chose alternative breast cancer treatments for years before her death this month. Here’s what she tried and what ...

A new research paper was published in Volume 16 of Oncotarget on June 17, 2025, titled "Molecular landscape of HER2-mutated ...